

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dominique Bourel et al.
Title: Novel Ig Fractions Having
Immunomodulatory Activity
Appl. No.: Unassigned
Filing Date: December 7, 2001
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

In order to comply with Applicant's duty of disclosure pursuant to 37 C.F.R. §1.56, submitted herewith on Form PTO-1449 is a listing of documents cited in the International Search Report of Applicants' International Application No. PCT/FR00/01560. A copy of the International Search Report setting forth the portion of each reference considered relevant by the Examiner is attached.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

09/980833

Att. No. 06569107 DEC 2001

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Michael D. Kammeli
By Reg. No. 32,904, for

Date: September 7, 2001

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 065691-0260	SERIAL NO. 67 DEC 2001				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Dominique Bourel et al.					
		FILING DATE 12/07/2001	GROUP ART UNIT Unassigned				
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A1	DIETRICH et al., "A V region-connected autoreactive subfraction of normal human serum immunoglobulin G," <i>European Journal of Immunology</i> 22(7), pp. 1701-1706 (July 1992).					
	A2	JORDAN et al., "Posttransplant therapy using high-doses human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action," <i>Transplantation</i> 66(6), pp. 800-805 (September 1998).					
	A3	PACHECO-GARCIA et al "Altered pattern of connectivity in serum immunoglobulins from pemphigus vulgaris patients," <i>Scandinavian Journal of Immunology</i> 49(4), pp. 424-430 (April 1999).					
	A4	FLAN, B. "Fractionation technique and biochemical properties of IV Ig! Technique de Fractionnement et Proprietes Biochimiques des Immunoglobulines Intraveineuses (IGIV)," <i>Sang Thrombose Vaisseaux</i> 11/Spec. Iss. (45-51), (October 1999).					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							